Results 21 to 30 of about 16,658,609 (280)

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas

, 2022
CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin’s lymphomas treated with CD19CAR T ...
Christian Martin Seitz, Seitz, Christian Martin, Sophia Scheuermann, Lara Ruoff, Patrick Schlegel, Ruoff, Lara, Mast, Anna-Sophia, Schlegel, Patrick, Daniel Atar, Anna-Sophia Mast, Scheuermann, Sophia, Atar, Daniel   +11 more
core   +1 more source

Advances in Universal CAR-T Cell Therapy

Frontiers in Immunology, 2021
Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements results in antitumor treatments, especially against hematological malignancies, where it leads to remarkable, long-term antineoplastic effects with higher target ...
Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou, Li Zhu   +4 more
doaj   +1 more source

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. [PDF]

, 2022
Chimeric antigen receptor T-cells (CAR T) treatment has become a standard option for patients with diffuse large B-cell lymphomas (DLBCL), which are refractory or relapse after two prior lines of therapy.
Rentsch, Vera, Pabst, Thomas, Porret, Naomi, Katja Seipel, Thomas Pabst, Wiedemann, Gertrud, Gertrud Wiedemann, Naomi Porret, Banz, Yara, Ulrike Bacher, Vera Rentsch, Seipel, Katja, Bacher, Ulrike, Yara Banz   +13 more
core   +2 more sources

Donor T cells for CAR T cell therapy

Biomarker Research, 2022
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed.
Tiffany C. Y. Tang, Ning Xu, Robert Nordon, Michelle Haber, Kenneth Micklethwaite, Alla Dolnikov   +5 more
doaj   +1 more source

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections

, 2021
Adoptive cell transfer (ACT) has long been at the forefront of the battle with cancer that began last century with the therapeutic application of tumor-infiltrating lymphocytes (TILs) against melanoma.
Irina Ganeeva, Emil Bulatov, Albert Rizvanov, Ekaterina Zmievskaya, Alexey Petukhov, Aygul Valiullina   +5 more
core   +1 more source

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma [PDF]

, 2022
Mantle cell lymphoma (MCL) is a rare type of B-cell Non-Hodgkin lymphoma (NHL) affecting predominantly male patients. While complete remissions following first-line treatment are frequent, most patients ultimately relapse, with a usually aggressive ...
Urban Novak, Heini, Alexander D., Legros, Myriam, Pabst, Thomas, Myriam Legros, Porret, Naomi, Katja Seipel, Stalder Zeerleder, Denise, Alexander D. Heini, Thomas Pabst, Naomi Porret, Gertrud Wiedemann, Wiedemann, Gertrud, Ulrike Bacher, Daskalakis, Michael, Denise Stalder Zeerleder, Heini, Alexander D, Seipel, Katja, Bacher, Ulrike, Michael Daskalakis, Novak, Urban   +20 more
core   +2 more sources

Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells

, 2023
With greater accessibility and an increased number of patients being treated with CAR T cell therapy, real-world toxicity continues to remain a significant challenge to its widespread adoption.
Tara Sadeghi, Christopher R. Flowers, Krina K. Patel, Paolo F. Caimi, Marcos de Lima, Simrit Parmar, Joseph D. Khoury, Meixian Huang, Mi-Ae Lyu, Ke Zeng, Sairah Ahmed, Boro Dropulić, Jane Reese-Koc   +12 more
core   +1 more source

Complications after CD19+ CAR T-Cell Therapy [PDF]

, 2020
Clinical trials demonstrated that CD19+ chimeric antigen receptor (CAR) T-cells can be highly effective against a number of malignancies. However, the complete risk profile of CAR T-cells could not be defined in the initial trials.
Penack, Olaf, Christian Koenecke, Koenecke, Christian, Olaf Penack   +3 more
core   +1 more source

Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma [PDF]

, 2023
Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (
Pabst, Thomas, Nilius, Henning, Katja Seipel, Dilara Akhoundova, Thomas Pabst, Banz, Yara, Ulrike Bacher, Akhoundova, Dilara, Frey, Michèle, Henning Nilius, Seipel, Katja, Bacher, Ulrike, Michèle Frey, Yara Banz   +13 more
core   +2 more sources

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

Frontiers in Immunology, 2022
The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies.
Feifei Nan, Xiaorui Fu, Xinfeng Chen, Ling Li, Xin Li, Jingjing Wu, Xiaoyan Feng, Xiaolong Wu, Jiaqin Yan, Mingzhi Zhang   +9 more
doaj   +1 more source